- Home
- SIEB vs AVTX Comparison
SIEB vs AVTX Comparison
Compare SIEB & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIEB
- AVTX
- Stock Information
- Founded
- SIEB 1886
- AVTX 2011
- Country
- SIEB United States
- AVTX United States
- Employees
- SIEB N/A
- AVTX N/A
- Industry
- SIEB Investment Bankers/Brokers/Service
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SIEB Finance
- AVTX Health Care
- Exchange
- SIEB Nasdaq
- AVTX Nasdaq
- Market Cap
- SIEB 95.1M
- AVTX 88.4M
- IPO Year
- SIEB N/A
- AVTX 2015
- Fundamental
- Price
- SIEB $3.01
- AVTX $8.01
- Analyst Decision
- SIEB
- AVTX Strong Buy
- Analyst Count
- SIEB 0
- AVTX 7
- Target Price
- SIEB N/A
- AVTX $34.33
- AVG Volume (30 Days)
- SIEB 16.7K
- AVTX 110.1K
- Earning Date
- SIEB 05-20-2025
- AVTX 05-12-2025
- Dividend Yield
- SIEB N/A
- AVTX N/A
- EPS Growth
- SIEB 61.43
- AVTX N/A
- EPS
- SIEB 0.33
- AVTX N/A
- Revenue
- SIEB $83,639,000.00
- AVTX $441,000.00
- Revenue This Year
- SIEB N/A
- AVTX N/A
- Revenue Next Year
- SIEB N/A
- AVTX N/A
- P/E Ratio
- SIEB $8.64
- AVTX N/A
- Revenue Growth
- SIEB 27.81
- AVTX N/A
- 52 Week Low
- SIEB $1.41
- AVTX $5.99
- 52 Week High
- SIEB $3.34
- AVTX $22.47
- Technical
- Relative Strength Index (RSI)
- SIEB 70.18
- AVTX 51.73
- Support Level
- SIEB $2.69
- AVTX $7.88
- Resistance Level
- SIEB $2.76
- AVTX $9.00
- Average True Range (ATR)
- SIEB 0.18
- AVTX 0.77
- MACD
- SIEB 0.07
- AVTX 0.08
- Stochastic Oscillator
- SIEB 85.15
- AVTX 37.87
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a holding company. It conducts retail discount brokerage business through its wholly-owned subsidiary. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).